Masao YARITA

Mr. Masao YARITA

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
SJSandra Jokšaitė
Sandra Jokšaitė
RWRobert Wood
Robert Wood
AIAfisi Ismaila
Afisi Ismaila
LCLucinda Camidge
Lucinda Camidge
AMAkiko Mizukami
Akiko Mizukami
KRKieran J Rothnie
Kieran J Rothnie
Objectives To evaluate and compare medication adherence and persistence for patients newly initiating single-inhaler triple therapy (SITT) and multiple-inhaler triple therapy (MITT) for chronic obstructive pulmonary disease (COPD) in Japan. Design Retrospective, new-user, active comparator, observational cohort study using inverse probability of treatment weighting. Setting Health insurance claims data from the Medical Data Vision Co., Ltd, hospital claims database. Participants Adults diagnosed with COPD at age ≥40 years newly initiating MITT or SITT (fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or formoterol fumarate/budesonide/glycopyrronium) from 1 September 2019 to 31 July 2021. Primary and secondary outcome measures The primary outcome was medication adherence compared between patients using SITT and MITT, assessed by the proportion of days covered ≥80%. Secondary outcomes included medication persistence (time from index treatment initiation to discontinuation) compared between patients using SITT and MITT and medication adherence compared before and after the switch in a subgroup of patients switching from MITT to SITT. Results We included 2575 MITT and 2962 SITT users with similar baseline characteristics following weighting. The proportion of adherent patients was significantly greater for SITT versus MITT users at 6 months (19.7% vs 10.2%, p<0.0001), 12 months (6.0% vs 3.8%, p=0.0009) and 18 months (3.8% vs 1.4%, p<0.0001) post-index. Median persistence was also significantly higher for SITT versus MITT users (2.0 vs 1.0 months, p<0.001). Comparing specific SITT versus MITT, the proportion of adherent patients at each time point and median persistence was greater for FF/UMEC/VI. In patients switching from MITT to SITT (n=688), the proportion of adherent patients increased postswitch at the class level and for FF/UMEC/VI specifically. Conclusions Patients with COPD in Japan who were newly initiating SITT had greater medication adherence and persistence compared with those on MITT up to 18 months following initiation.

1 March 2025 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
GRGema Requena
Gema Requena
LCLucinda J Camidge
Lucinda J Camidge
AFAlexander Ford
Alexander Ford
MYMasao YARITA
Masao YARITA
KHKenichi Hashimoto
Kenichi Hashimoto
AMAkiko Mizukami
Akiko Mizukami
Purpose: Following the relatively recent introduction of single-inhaler triple therapies in Japan, this study compared the effectiveness of switching from multiple-inhaler triple therapy (MITT) to once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) by investigating COPD exacerbations and adherence among patients with chronic obstructive pulmonary disease (COPD) in Japan. Methods: This retrospective, pre–post cohort study using the Medical Data Vision Co. Ltd database identified patients with ≥ 1 inpatient diagnosis and/or ≥ 2 outpatient diagnoses of COPD at age ≥ 40 years prior to the index date (first/earliest date of single-inhaler FF/UMEC/VI initiation from May 1, 2019–February 28, 2022, following a switch from MITT). The proportion of patients with ≥ 1 overall (moderate-to-severe), moderate, or severe COPD exacerbation and rate of exacerbations were assessed at 6 months pre- and post-index. Medication adherence (proportion of days covered [PDC]) was also assessed. Results: In total, 2365 patients were included, with a mean (standard deviation) age of 75.3 (9.7) years, and 77.1% were male. In the 6 months post-switch from MITT to FF/UMEC/VI, there was a statistically significant decrease in the proportion of patients who experienced ≥ 1 overall (11.2% to 8.8%; p=0.0014) and severe exacerbation (4.6% to 3.2%; p=0.0069). There was a similar proportion of patients who experienced ≥ 1 moderate exacerbation pre- and post-switch (6.9% to 6.2%; p=0.2394). Rates of overall (rate ratio [RR]: 0.86, 95% confidence interval [CI]: 0.74– 1.00; p=0.0528) and moderate exacerbations (RR: 0.95, 95% CI: 0.79– 1.13; p=0.5796) were numerically lower post-switch. There was a significant reduction in severe exacerbations post-switch (RR: 0.68, 95% CI: 0.51– 0.90; p=0.0084). Mean PDC was significantly higher in the 6 months post- versus pre-switch (0.83 versus 0.80; p< 0.0001). Conclusion: Patients who switched from MITT to FF/UMEC/VI had reduced exacerbations and improved adherence. These results may help inform healthcare providers on the optimum management strategy for patients with COPD in Japan. Plain Language Summary: Current guidelines recommend that patients with chronic obstructive pulmonary disease (COPD) who experience exacerbations (flare-ups of their symptoms) should be treated with a combination of three treatments, known as triple therapy. Patients can receive multiple-inhaler triple therapy (MITT) or single-inhaler triple therapy (SITT). SITT offers an easier and more convenient treatment plan than MITT and has been shown to improve adherence (the extent to which patients use their treatments as recommended/prescribed). Two SITTs have been approved for use in Japan, including once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI). Following the relatively recent introduction of SITTs in Japan, this study compared the effectiveness of switching from MITT to FF/UMEC/VI by investigating COPD exacerbations and adherence among patients with COPD in Japan. Patients included in this study were identified from the Medical Data Vision Co. Ltd database, who had switched from using MITT to using FF/UMEC/VI. We assessed COPD exacerbations and adherence to treatment in the 6 months before patients switched from MITT to FF/UMEC/VI and the 6 months following the switch. We found that patients who switched from MITT to FF/UMEC/VI had lower rates of exacerbations in the 6 months after the switch compared with the 6 months before the switch. Patients also had improved treatment adherence in the 6 months post-switch compared with the 6 months pre-switch. The findings of this study may help healthcare providers to prescribe the best treatment plan for patients with COPD in Japan, to help improve their treatment outcomes.

Verified
Journal Article
Open access
PDF file
Toru OgaToru Oga
Toru Oga
YGYasuhiro Gon
Yasuhiro Gon
MTMasashi Takano
Masashi Takano
RIRisako Ito
Risako Ito
CIChifuku Ito
Chifuku Ito
MYMasao YARITA
Masao YARITA
Background: Japanese guidelines recommend the addition of a long-acting muscarinic antagonist for patients with asthma uncontrolled on inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) therapy, the effectiveness of which is evaluated here. Methods: Retrospective, observational, single-arm cohort study in patients with asthma initiating fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) following ICS/LABA, using independently analyzed data from Japanese claims databases: JMDC and Medical Data Vision (MDV). The index date was that of the first FF/UMEC/VI prescription. Outcomes were assessed during a 12-month follow-up versus a 12-month pre-index period (baseline) and included asthma exacerbations, oral corticosteroid (OCS) use, and short-acting β2-agonist (SABA) use. P-values associated with rate ratios (RRs) were estimated using Conditional Poisson regression. Results: Overall, 3229 patients in the JMDC database and 1135 in the MDV database were included. Following FF/UMEC/VI initiation, the total annualized moderate–severe asthma exacerbation rate in the JMDC database reduced from 0.50 to 0.40 per-person-per-year (PPPY) (RR [95% confidence interval]: 0.78 [0.73, 0.84]; p < 0.001), with similar reductions in the MDV database: 0.53 to 0.42 PPPY (0.79 [0.70, 0.89]; p < 0.001). In both databases, there was a 20% reduction (JMDC: 0.80 [0.73, 0.88]; p < 0.001; MDV: 0.80 [0.68, 0.94]; p = 0.005) in patients with ≥1 OCS prescription after FF/UMEC/VI initiation. The proportion of patients with ≥1 SABA canister prescription dropped by 31% 0.69 [0.57, 0.84]; p < 0.001) in the JMDC database and 23% (0.77 [0.66, 0.90]; p < 0.001) in the MDV database. Conclusions: This suggests FF/UMEC/VI is effective in improving asthma exacerbations and reducing OCS and SABA use in Japanese patients previously using ICS/LABA in real-world clinical practice.

3 August 2025 in Current Medical Research and Opinion
Verified
Journal Article
Open access
MTMasashi Takano
Masashi Takano
KSKazuko Suzuki
Kazuko Suzuki
STSakiyo Tsukamoto
Sakiyo Tsukamoto
YNYasuo Nakajima
Yasuo Nakajima
HOHirofumi Ozeki
Hirofumi Ozeki
AHAi Hayashi
Ai Hayashi
HIF-PHI inhibitors, including daprodustat, have expanded treatment options for patients with renal anaemia in Japan. This analysis examines real-world utilization of daprodustat in Japan, for which data are currently lacking. This retrospective cohort study analyzed patient characteristics, treatment patterns, and management of renal anaemia in individuals aged >15 years who were treated with daprodustat between 1 August 2020 and 1 July 2023 using an anonymized electronic medical record database. Patients were assigned to dialysis-dependent (DD) and nondialysis-dependent (ND) cohorts. This study included 1299 patients (111 DD cohort; 1188 ND cohort). Mean age was 71.0 and 79.2 years in the DD and ND cohorts, respectively. In both cohorts, hypertension, heart failure, oesophageal gastric erosion, and type 2 diabetes mellitus were frequent comorbidities. In the DD cohort, 31.5% of patients had Hb levels of 9-10 g/dL at baseline and in the ND cohort 35.9% had Hb levels <9 g/dL at baseline. Prior to the index date, 72 patients in the DD cohort (64.9%) and 635 patients (53.5%) in the ND cohort were treated for anaemia. In patients who switched from erythropoiesis-stimulating agents to daprodustat, mean haemoglobin increased from 9.9 g/dL at baseline to 10.8 g/dL in the DD cohort (n = 23; Wilcoxon sign-ranked test [WSRT] p = 0.0148) and from 9.6 g/dL at baseline to 10.4 g/dL in the ND cohort (n = 92; WSRT p < 0.0001) 28 weeks after daprodustat initiation. Approximately a third (DD) to almost half (ND) of patients with renal anaemia were not receiving treatment for anaemia. An increase in haemoglobin levels was observed after initiation of daprodustat, including in patients previously treated with erythropoiesis-stimulating agents, however causality cannot be confirmed due to lack of a control group.